Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Literature
1.
Garrido-Siles M, Arenas-Villafranca JJ, Pérez-Ruiz E, de Linares Fernández MF, Tortajada B, Rivas-Ruiz F, Faus V, Rueda A (2014) New cutaneous toxicities with generic docetaxel: are the excipients guilty? Support Care Cancer
2.
Vial J, Cohen M, Sassiat P, Thiébaut D (2008) Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis. Curr Med Res Opin 24:2019–2033CrossRefPubMed
Metadata
Title
Letter to the editor
Authors
S. Boutayeb
I. El ghissassi
S. Naceri
N. Berrada
H. Mrabti
H. Errihani
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2790-x

Other articles of this Issue 10/2015

Supportive Care in Cancer 10/2015 Go to the issue

Original Article

Exercise compliance among patients with multiple myeloma undergoing chemotherapy: a retrospective study

Original Article

Variations in intensity of end-of-life cancer therapy by cancer type at a Canadian tertiary cancer centre between 2003 and 2010

Original Article

Comparing men’s and women’s experiences of work after cancer: a photovoice study

Commentary

Acceptance and commitment therapy program for distressed adults with a primary brain tumor: a case series study

Original Article

Inpatient infectious disease consultations requested by surgeons at a comprehensive cancer center

Original Article

Does routine symptom screening with ESAS decrease ED visits in breast cancer patients undergoing adjuvant chemotherapy?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits